Building an efficient open-source system for drug development is ethically compelling. Yet, from an economic standpoint, it's far less appealing—especially for pharmaceutical labs.
Imagine sharing research data freely to fast-track treatments for diseases—a dream for many, but a nightmare for labs that tightly control their teams' discoveries, drug production, and marketing. Even after patents expire, key results often stay proprietary. Establishing a true open-source drug development system thus feels utopian.
David Mitchell, founder of Patients for Affordable Drugs, told Fast Company on April 30, 2020, that the U.S. prescription drug pricing system prioritizes profits over patients. His advocacy highlights how it operates as a money-making machine rather than a public service.
Enter Jaykumar Menon, a human rights lawyer and founder of the Open Source Pharma Foundation (OSPF). This platform gives scientists free access to tools for disease research, enabling them to share data and launch collaborative projects. It bypasses traditional economic barriers to accelerate drug development.
OSPF draws GitHub comparisons for its collaborative model, but drugs aren't software—they demand rigorous peer validation. Success hinges on broad researcher participation. Since 2018, OSPF has notched a win with Metformin, a diabetes generic now in phase 2B trials for tuberculosis. Developed for just $50,000—versus the industry's typical $2.5 billion—this milestone signals open-source potential in biomedical research, better equipping us for future pandemics.
